Brief: Clover Announces Positive Phase 2/3 Results In Adolescents For COVID-19 Vaccine

Dynavax Technologies

25/08/2022 11:28

Aug 25 (Reuters) - Clover Biopharmaceuticals Ltd  2197.HK :
    * CLOVER ANNOUNCES POSITIVE PHASE 2/3 RESULTS IN ADOLESCENTS
FOR
ITS COVID-19 VACCINE
    * CLOVER BIOPHARMACEUTICALS LTD- RESULTS SHOW FAVORABLE
TOLERABILITY AND SAFETY PROFILE IN ADOLESCENTS, CONSISTENT WITH
RESULTS PREVIOUSLY OBSERVED IN ADULTS
    * CLOVER BIOPHARMACEUTICALS LTD - STUDY SUCCESSFULLY MET
PRIMARY
ENDPOINT
    * CLOVER BIOPHARMACEUTICALS LTD-  PLANS TO SUBMIT ADOLESCENT
DATA
TO GLOBAL REGULATORY AUTHORITIES
    * CLOVER BIOPHARMACEUTICALS LTD - ADVERSE EVENTS WERE MOSTLY
MILD
AND TRANSIENT
    * CLOVER BIOPHARMACEUTICALS LTD -  SCB-2019 ELICITED
APPROXIMATELY
2-FOLD HIGHER NEUTRALIZING ANTIBODY TITERS IN ADOLESCENTS
COMPARED TO YOUNG ADULTS

Source text for Eikon:  ID:nGNX9zxdsP 
Further company coverage:  2197.HK 

 ((Reuters.Briefs@thomsonreuters.com;))